In a strategic move towards advancing cancer therapy, pharmaceutical giant AstraZeneca has entered into a collaboration with Absci, a leading artificial intelligence (AI) biologics firm based in the United States. The deal, valued at up to $247 million, focuses on leveraging Absci’s AI technology for large-scale protein analysis to design an innovative antibody aimed at ... Read more